ESMO real world data and digital oncology
Aug 3, 2026
BACKGROUND: The AI-HOPE Lung Cancer study is a multicenter initiative designed to integrate artificial intelligence (AI) and real-world data to improve outcome prediction in patients with metastatic non-small-cell lung cancer treated with first-line ...
ESMO real world data and digital oncology
Jul 23, 2026
BACKGROUND: Early discontinuation (ED) in clinical trials (CTs) is frequent and deleterious for the patients, the care team, and the study duration. ED comprises screening failure or discontinuation during the first month of the treatment phase, and ...
ESMO real world data and digital oncology
Jul 14, 2026
Artificial intelligence (AI) is rapidly reshaping oncology, from diagnosis to treatment planning and clinical research. This perspective defines the oncologist in the era of AI as a clinician able to critically interpret, supervise, and communicate A...
ESMO real world data and digital oncology
Jun 30, 2026
[This corrects the article DOI: 10.1016/j.esmorw.2025.100146.].
ESMO real world data and digital oncology
Jun 15, 2026
BACKGROUND: Early-phase oncology trials involve complex protocols and extensive documents, making timely resolution of study queries challenging. We developed the Study Document Assistant (SDA), a retrieval-augmented generation (RAG) system that inte...
ESMO real world data and digital oncology
May 20, 2026
Artificial intelligence (AI) is increasingly entering oncology, with systems demonstrating physician-comparable performance in selected tasks such as imaging interpretation, digital pathology analysis, and clinical documentation. However, limitations...
ESMO real world data and digital oncology
Apr 17, 2026
BACKGROUND: Real-world data collection in oncology remains a challenge due to the complex and unstructured format of medical notes. Recently, large language models (LLMs) have demonstrated success in extracting information from free-text data across ...
ESMO real world data and digital oncology
Apr 14, 2026
BACKGROUND: Lack of readily available recurrence data has limited the use of electronic health records (EHR) for risk assessment of cancer recurrence and optimal patient management. This study aims to derive high-quality EHR recurrence data and estim...
ESMO real world data and digital oncology
Apr 14, 2026
BACKGROUND: The assessment of estrogen/progesterone receptors (ER/PR) and human epidermal growth factor receptor 2 (HER2) is essential for managing breast cancer (BC) patients, as these biomarkers guide targeted therapies. Traditional methods such as...
ESMO real world data and digital oncology
Apr 7, 2026
BACKGROUND: Unstructured oncology consultation notes contain rich clinical information that may support survival prediction. Open-weight large language models (LLMs) can utilize these notes with zero-shot inference or fine-tuning, but their relative ...